z-logo
open-access-imgOpen Access
Chronic hepatitis C-associated thrombocytopenia: aetiology and management
Author(s) -
Yasser Fouad
Publication year - 2013
Publication title -
tropical gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 2320-5792
pISSN - 0250-636X
DOI - 10.7869/tg.2012.99
Subject(s) - medicine , immunology , platelet , hepatitis c virus , interferon , etiology , immune thrombocytopenia , platelet transfusion , immune system , hepatitis c , virus , gastroenterology
Thrombocytopenia is perhaps the most common haematological abnormality in patients with chronic hepatitis C virus (HCV) infection. In these patients, the presence of thrombocytopenia may be a limiting factor when considering antiviral therapy and may be associated with decreased sustained virological response rates. Thrombocytopenia may interfere with diagnostic procedures such as liver biopsy, because of risk of bleeding. Pathogenetic mechanisms include hypersplenism secondary to portal hypertension, bone marrow suppression resulting from either HCV itself or interferon treatment, and aberrations of the immune system resulting in the formation of anti-platelet antibodies and/or immune-complexes that bind to platelets and facilitate their premature clearance. The ability to increase platelet levels could significantly reduce the need for platelet transfusions and facilitate the use of interferon-based antiviral therapy and other medically indicated treatments in patients with liver disease. Therapeutic options include pharmacological and non-pharmacological therapies. This review summarizes the available data on these therapeutic options.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here